Evidence map›Paper›PMID 31546119›Full record

ArticleDrug and alcohol dependence2019

Opioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment.

Kathleen A McGinnis, David A Fiellin, Melissa Skanderson, Yih-Ing Hser, Gregory M Lucas, Amy C Justice, Janet P Tate, VACS Project Group

Abstract read
In one paragraph

Article in Drug and alcohol dependence, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kathleen A McGinnisVeterans Affairs Connecticut Healthcare System, West Haven, CT, USA. Electronic address: kathleen.mcginnis3@va.gov.
David A FiellinDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, USA.
Melissa SkandersonVeterans Affairs Connecticut Healthcare System, West Haven, CT, USA.
Yih-Ing HserIntegrated Substance Abuse Programs, Univeristy of California Los Angeles, Los Angeles, CA, USA.
Gregory M LucasDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Amy C JusticeVeterans Affairs Connecticut Healthcare System, West Haven, CT, USA; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Janet P TateVeterans Affairs Connecticut Healthcare System, West Haven, CT, USA; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
VACS Project Group

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Alcohol Associated Outcomes Among HIV+/- Aging VeteransU10AA013566 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2006 to 2010
$12.7M
Alcohol and Multisubstance Use in the Veterans Aging Cohort StudyU01AA020790 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2011 to 2020
$7.7M
Sex Disparities in Overall Response to ART Among HIV Infected IndividualsU24AA020794 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2011 to 2020
$5.5M
Integrated Stepped Care for Unhealthy Alcohol Use in HIVU01AA020795 · NIAAA · YALE UNIVERSITY · PI FIELLIN, DAVID · 2011 to 2020
$5.2M
3/3 COMpAAAS Tripartite: ART-CC, KP, and VAU01AA026224 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2017 to 2021
$2.9M
Consortium to improve Outcomes in HIV/AIDS, Alcohol, Aging & multi-Substance useU01AA020799 · NIAAA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BRAITHWAITE, RONALD SCOTT · 2011 to 2020
$2.1M
Treatment outcomes and comorbidity in HIV-infected IDUK24DA035684 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M · 2014 to 2024
$1.5M
Using the VACS Index to track health outcomes associated with changes in drug useR01DA035616 · NIDA · YALE UNIVERSITY · PI FIELLIN, DAVID, JUSTICE, AMY CAROLINE · 2013 to 2015
$1.2M
NCATS NIH HHS UL1 TR001863NIAAA NIH HHS U01 AA020790NIAAA NIH HHS U01 AA020795NIAAA NIH HHS U01 AA020799NIAAA NIH HHS U01 AA026224NIAAA NIH HHS U10 AA013566NIAAA NIH HHS U24 AA020794NIDA NIH HHS K24 DA035684NIDA NIH HHS R01 DA035616
6 · The paper itself

Abstract

backgroundObjective outcomes for measuring the physical health effects of substance use disorder treatment are needed. We compared the responsiveness of CD4, HIV-1 RNA and a biomarker index (VACS Index 2.0) to changes in opioid use among people with HIV (PWH) and uninfected individuals receiving opioid agonist treatment (OAT).

methodsElectronic health record data were used to identify patients who received ≥90 days of OAT and had ≥1 urine toxicology test in the Veterans Aging Cohort Study. Trajectory models identified patterns of opioid urine toxicology results. We used linear regression adjusted for age and race/ethnicity to determine associations between opioid toxicology groups and biomarker changes from up to one-year pre OAT to 3-15 months after OAT initiation.

resultsAmong 266 with detectable HIV-1 RNA, 366 with suppressed HIV-1 RNA, and 1183 uninfected patients, we identified five opioid toxicology groups ranging from consistently negative (54%) to consistently positive (9%). Among PWH with detectable HIV-1 RNA, all three biomarkers improved more for those consistently negative compared to those consistently positive (all p < .05). Among PWH with suppressed HIV-1 RNA, CD4 improved for those consistently negative; and worsened for those in the slow decrease toward negative group (p = .04). Among those uninfected, VACS Index 2.0 did not differ by opioid toxicology groups.

conclusionsAmong patients on OAT, changes in biomarkers are associated with opioid toxicology groups among PWH, but vary by HIV-1 RNA. These findings may be useful for measuring the health effects of OAT.

Indexed as

HIV-1AdultAnalgesics, OpioidBiomarkersFemaleHIV InfectionsHumansLinear ModelsMaleMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersRNA, ViralAnalgesics, OpioidBiomarkersRNA, ViralBuprenorphineCD4HIVHIV-1 RNAMethadoneVACS index

Identifiers

PMID31546119
PMCPMC6993986

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.